UBS BB sees Hapvida recovery signs but keeps neutral, demands proof

UBS BB acknowledges clear evidence of Hapvida's operational recovery but maintains a neutral rating, citing need for further proof. The stock may have priced in worst-case scenarios, but the bank's cautious stance reflects uncertainty about sustainability. This matters as it signals a potential inflection point for the Brazilian healthcare operator, though confirmation is pending.